The Alzheimer’s Drug Discovery Foundation (ADDF) announces $2.5 million in new funding, which reflects the comprehensive nature of our strategy to prevent and treat Alzheimer’s disease. These 10 new projects encompass clinical trials, innovative drug discovery, prevention research, biomarkers development, and the advancement of the entire field through collaborations and conferences.
Dr. Howard Fillit, Founding Executive Director and Chief Science Officer of the ADDF, noted: “The ADDF understands the enormous effort required to conquer Alzheimer’s disease. We don’t take a ‘one-size-fits-all’ approach, instead choosing to pursue every avenue necessary to help all patients with Alzheimer’s disease.”
Treatments
CLINICAL
Paul Edison, MD, Imperial College, London
Evaluating the Effects of the Novel GLP-1 Analogue, Liraglutide, in Patients with…
